Drug profile · INN
revumenib citrate
REVUFORJ
revumenib citrate (REVUFORJ) is a menin inhibitor. Associated with Syndax Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — revumenib citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 13
- Data quality
- 0.89
Quick answer
revumenib citrate (REVUFORJ) is a menin inhibitor. Associated with Syndax Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Menin inhibitor
Primary target: Menin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Frequently asked questions
What is revumenib citrate?
revumenib citrate (REVUFORJ) is a menin inhibitor. Associated with Syndax Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for revumenib citrate?
REVUFORJ is a marketed brand name for revumenib citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of revumenib citrate?
revumenib citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.